J7682
J7682 – Tobramycin, inhalation solution, fda-approved final product, non-compoun · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 26 NDCs crosswalked per 300 MG $12.305/unit ASP+6%
📋 J7682 summary
J7682 is a HCPCS Level II J-code used to bill Tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose for..., billed per 300 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J7682: Bethkis*, Tobramycin, Bethkis
Code J7682
Billing unit 300 MG Payment limit $12.305/unit NDC-Crosswalk 26
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ7682
DescriptorTobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligrams
Billing unit300 MG
Payment limit / unit$12.305
Est. ASP / unit$11.608 est.
Mapped NDCs26
Data periodQ3 2026
Last updated2026-08-20
💊 About Tobramycin DRUG GUIDE
Tobramycin treats several types of bacterial infections depending on how it is given.
Inhaled forms (including TOBI, Bethkis, Kitabis Pak, TOBI Podhaler, and tobramycin inhalation solution products) are used to manage cystic fibrosis in adults and children 6 years and older who have a lung infection caused by Pseudomonas aeruginosa.
Tobramycin ophthalmic products (Tobrex ointment and tobramycin ophthalmic solution) treat bacterial infections of the eye and surrounding area.Tobramycin injection is used to treat serious bacterial infections including bloodstream infections (septicemia), lower respiratory tract infections, meningitis, intra-abdominal infections (including peritonitis), skin and bone infections, and complicated urinary tract infections caused by susceptible bacteria.
Clinical overview from our editorial drug guide for Tobramycin. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$12.305
Est. ASP / unit
$11.608 est.
Est. after 2% sequester
$12.059
HCPCS dosage
300 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionTobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligrams
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2D1G
ASC payment group—
Action codeN — No maintenance this year
Effective date2007-01-01
Date added2000-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J7682 = 300 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J7682 LEAST EXPENSIVE FIRST
26 NDCs map to J7682. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($12.305/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00093-4085-63 | Tobramycin 300 mg/5mL SOLUTION | Teva | 56 AMPULE in 1 CARTON (0093-4085-63) / 5... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 42571-0408-92 | Tobramycin 300 mg/5mL INHALANT | Micro | 14 POUCH in 1 CARTON (42571-408-92) / 4 A... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 43598-0605-56 | Tobramycin Inhalation Solution 300 mg/5mL INHALANT | Dr. | 14 POUCH in 1 CARTON (43598-605-56) / 4 A... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 43598-0605-58 | Tobramycin Inhalation Solution 300 mg/5mL INHALANT | Dr. | 56 POUCH in 1 CARTON (43598-605-58) / 1 A... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 47335-0171-49 | Tobramycin 300 mg/5mL SOLUTION | Sun | 14 POUCH in 1 CARTON (47335-171-49) / 4 A... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 65162-0914-46 | Tobramycin 300 mg/5mL SOLUTION | Amneal | 56 AMPULE in 1 CARTON (65162-914-46) / 5... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 68180-0962-56 | Tobramycin 300 mg/5mL SOLUTION | Lupin | 56 POUCH in 1 CARTON (68180-962-56) / 4 A... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 70756-0604-56 | TOBRAMYCIN 300 mg/5mL SOLUTION | Lifestar | 14 POUCH in 1 CARTON (70756-604-56) / 4 A... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 72603-0430-56 | TOBRAMYCIN 300 mg/5mL SOLUTION | NorthStar | 14 POUCH in 1 CARTON (72603-430-56) / 4 A... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 76204-0029-56 | Tobramycin 300 mg/5mL SOLUTION | Ritedose | 14 POUCH in 1 CARTON (76204-029-56) / 4 A... | 300 mg/5mL | 56 | $689.08 | $1.085 | ● Active | CMS + PDAC |
| 67877-0678-70 | Tobramycin 300 mg/5mL SOLUTION | Ascend | 56 POUCH in 1 CARTON (67877-678-70) / 7 A... | 300 mg/5mL | 0.2 | $2.46 | $1.085 | ● Active | PDAC |
| 00093-3750-28 | Tobramycin 300 mg/4mL SOLUTION | Teva | 7 POUCH in 1 CARTON (0093-3750-28) / 4 AM... | 300 mg/4mL | 28 | $344.54 | — | Obsolete | CMS + PDAC |
| 00093-3750-63 | Tobramycin 300 mg/4mL SOLUTION | Teva | 14 POUCH in 1 CARTON (0093-3750-63) / 4 A... | 300 mg/4mL | 56 | $689.08 | — | Obsolete | CMS + PDAC |
| 10122-0820-28 | BETHKIS tobramycin 300 mg/4mL SOLUTION | Chiesi | 7 POUCH in 1 CARTON (10122-820-28) / 4 AM... | 300 mg/4mL | 28 | $344.54 | — | ● Active | CMS ASP |
| 10122-0820-56 | BETHKIS tobramycin 300 mg/4mL SOLUTION | Chiesi | 14 POUCH in 1 CARTON (10122-820-56) / 4 A... | 300 mg/4mL | 56 | $689.08 | — | ● Active | CMS + PDAC |
| 16714-0119-03 | Tobramycin inhalation | Northstar | — | — | 56 | $689.08 | — | — | CMS + PDAC |
| 24492-0850-56 | Kitabis Pak Tobramycin 300 mg/5mL SOLUTION | Pari | 14 POUCH in 1 CARTON (24492-850-56) / 4 A... | 300 mg/5mL | 56 | $689.08 | — | ● Active | CMS ASP |
| 49502-0345-73 | TOBI Tobramycin 300 mg/5mL SOLUTION | Viatris | 56 POUCH in 1 CARTON (49502-345-73) / 4 A... | 300 mg/5mL | 56 | $689.08 | — | ● Active | CMS + PDAC |
| 60687-0731-83 | Tobramycin 300 mg/5mL SOLUTION | American | 30 POUCH in 1 CARTON (60687-731-83) / 1 A... | 300 mg/5mL | 30 | $369.15 | — | ● Active | CMS ASP |
| 66993-0195-94 | Tobramycin Inhalation 300 mg/4mL SOLUTION | Prasco, | 14 POUCH in 1 CARTON (66993-195-94) / 4 A... | 300 mg/4mL | 56 | $689.08 | — | ● Active | CMS + PDAC |
| 70644-0899-99 | Tobramycin Inhalation Solution Pak 300 mg/5mL SOLUTION | Genericus, | 14 POUCH in 1 CARTON (70644-899-99) / 4 A... | 300 mg/5mL | 56 | $689.08 | — | ● Active | CMS + PDAC |
| 70756-0617-56 | Tobramycin 300 mg/4mL SOLUTION | Lifestar | 14 POUCH in 1 CARTON (70756-617-56) / 4 A... | 300 mg/4mL | 56 | $689.08 | — | ● Active | CMS + PDAC |
| 72603-0630-56 | Tobramycin 300 mg/4mL SOLUTION | NorthStar | 14 POUCH in 1 CARTON (72603-630-56) / 4 A... | 300 mg/4mL | 56 | $689.08 | — | ● Active | CMS + PDAC |
| 17478-0340-38 | TOBRAMYCIN (4 AMPULES X 14 POUCHES) 300 MG/5 ML | Unknown | — | — | 0.2 | $2.46 | — | — | PDAC |
| 00781-7171-56 | TOBRAMYCIN (PF) 300 MG/5 ML | Unknown | — | — | 0.2 | $2.46 | — | — | PDAC |
| 00078-0494-71 | TOBI (56X5ML,SDA,PF) | Unknown | — | — | 0.2 | $2.46 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$1.58M
Claims
2,369
Beneficiaries
1,726
Spend / beneficiary
$913.35
Spend / claim
$665.44
Trend by period
Where J7682 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #342 of 824
#337
ONTRUZANT Q5112
$1.65M
#338
ARFORMOTEROL TARTRAT... J7605
$1.64M
#339
CELLCEPT* J7517
$1.62M
#340
CORTROPHIN J0802
$1.6M
#341
AZACITIDINE* J9025
$1.58M
#342
BETHKIS* J7682
$1.58M
#343
EVEROLIMUS* J7527
$1.54M
#344
TEVIMBRA J9329
$1.52M
#345
TRAZIMERA Q5116
$1.52M
#346
EPOPROSTENOL SODIUM* J1325
$1.5M
#347
LEXISCAN* J2785
$1.48M
Total claims — #294 of 824
#289
CYCLOPHOSPHAMIDE(J90... J9072
2,490
#290
AFLURIA (90658)* 90658
2,467
#291
CAMCEVI J1952
2,453
#292
TRELSTAR J3315
2,409
#293
RYBREVANT J9061
2,396
#294
BETHKIS* J7682
2,369
#295
RIABNI Q5123
2,340
#296
GRANIX J1447
2,295
#297
RITUXAN HYCELA J9311
2,293
#298
ACETYLCYSTEINE J7608
2,256
#299
MOXIFLOXACIN J2280
2,225
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $1.58M | 1,726 | 2,369 | $913.35 | $665.44 |
| 2025 (Q1-Q4) | $9.61M | 3,827 | 11,857 | $2,512.35 | $810.89 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$9.78M
Medicare paid
$7.6M
Submitted services
679,973
Denial rate
5.6%
Allowed / service
$15.23
Submitted charges
$97.06M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J7682 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J7682
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
26 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J7682 billing FAQ
What is HCPCS code J7682?
J7682 is a HCPCS Level II J-code used to bill Tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligrams under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J7682?
One unit of J7682 represents 300 MG. Report the number of units equal to the dose administered divided by 300 MG.
How many units of J7682 should I bill?
Divide the dose administered by the code's unit size (300 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J7682?
The Medicare Part B payment limit is $12.305 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $12.059 per unit. Payment limits are revised quarterly.
Which NDCs bill under J7682?
26 NDCs currently map to J7682 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J7682 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.